Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

27%

4 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

6(42.9%)

Phase 3

4(28.6%)

Phase 2

4(28.6%)

14Total

Phase 1(6)

Phase 3(4)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT04573023Phase 3Active Not Recruiting

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Role: lead

NCT06488924Phase 1Active Not Recruiting

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Role: lead

NCT07640984Phase 1Recruiting

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Role: lead

NCT07615400Recruiting

A Long-Term Observational Study of Patients With Fucosidosis

Role: lead

NCT03708965Phase 2Active Not Recruiting

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Role: lead

NCT06095388Phase 1Active Not Recruiting

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Role: lead

NCT04348136Phase 2Active Not Recruiting

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Role: lead

NCT05594992Phase 3Enrolling By Invitation

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects

Role: lead

NCT04453085Phase 1Completed

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Role: lead

NCT03359213Phase 2Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)

Role: lead

NCT04227600Phase 1Completed

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Role: lead

NCT03568175Phase 2Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Role: lead

NCT03128593Phase 1Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Role: lead

NCT02912494Phase 3Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Role: collaborator

NCT02912533Phase 3Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Role: collaborator

All 15 trials loaded